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BLETTER TO THE EDITOR
e: Twenty-Year Follow-Up in Patients with Aplastic
nemia Given Marrow Grafts from HLA-Identical
iblings and Randomized to Receive Methotrexate/
yclosporine or Methotrexate Alone for Prevention
f Graft-versus-Host Disease
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sFrom December 1981 to March 1985, 46 patients
ith severe aplastic anemia were enrolled in a prospec-
ive randomized trial analyzing the safety and efﬁcacy of
ethotrexate/cyclosporine (n 22) versus methotrexate
lone (n  24) for prevention of acute graft-versus-host
isease (GVHD) after marrow transplantation from
LA-identical siblings [1]. Fewer methotrexate/cyclo-
porine-treated patients had grade II to IV acute
VHD (18%) compared with methotrexate-treated
atients (54%; P  .01). In addition, no patient given
ethotrexate/cyclosporine experienced grade III or
V acute GVHD, compared with 3 and 6 patients,
espectively, given methotrexate alone. The reduction
n acute GVHD was accompanied by a trend for
mproved early survival [1,2]. The current update with
ollow-up ranging from 18 to 23 years shows that the
urvival advantage suggested by early follow-up has
ersisted. Seventy-three percent of the methotrexate/
yclosporine-treated patients are alive, compared with
2% of the methotrexate-treated patients (P  .06;
igure 1A).
Patients were conditioned with cyclophosphamide
00 mg/kg body weight intravenously and were then
iven marrow grafts from HLA-identical siblings.
ostgrafting immunosuppression was either metho-
rexate on days 1, 3, 6, and 11 combined with cyclo-
porine for 6 months or methotrexate alone given on
ays 1, 3, 6, and 11 and then once weekly until day
02. Details on patient characteristics, stratiﬁcation
or risk factors, and the random assignment of post-
rafting immunosuppression were described in the
riginal article [1].
Three patients, 2 given methotrexate/cyclosporine
nd 1 given methotrexate, rejected their grafts (n  2)
r experienced graft failure (n  1). The 2 methotrex-
te/cyclosporine-treated patients were successfully
iven second transplants from the original marrow
onors 7 and 20 months after their ﬁrst transplanta-
ions, and they are alive with Karnofsky scores of h
B&MT00, whereas the methotrexate-treated patient died,
fter a second transplantation, from sepsis and com-
lications associated with chronic GVHD.
The prevalence curves [3] describing the onset of
hronic GVHD and its resolution in response to ther-
py were comparable for the 2 study arms (P  .40;
igure 1B). None of the methotrexate/cyclosporine-
reated patients and 1 methotrexate-treated patient
urrently continue on immunosuppression. Twelve of
6 surviving methotrexate/cyclosporine-treated pa-
ients have Karnofsky performance scores of 100,
nd 4 have scores of 90. All 10 surviving methotrex-
te-treated patients have scores of 100. Eighteen of
6 surviving patients are completely healthy; 4 pa-
ients are hepatitis C virus positive (this virus was
resumably acquired through preceding transfusions);
of the 4 recently developed diabetes mellitus; 1 has
umbosacral osteoarthritis and hypertension; 1 patient
as hypertension; and 1 patient had squamous cell
arcinoma of the skin that was surgically removed.
ive methotrexate/cyclosporine-treated patients died.
hree died from GVHD-related complications, in-
luding hepatic encephalopathy (day 199), sepsis (day
20), and bronchoalveolitis (day 950), and 2 patients
ied early, 1 from massive brain hemorrhage (day 12)
nd 1 from pulmonary and renal failure (day 3). Four-
een methotrexate-treated patients died. Six died from
VHD-associated complications, including dissemi-
ated aspergillosis and cytomegalovirus (CMV) dis-
ase (day 64), interstitial pneumonitis and CMV of the
ut (day 103), pneumonia and cerebral infarcts (day
08), sepsis (day 216), fulminant hepatic failure (day
38), and septic shock (day 726). Two methotrexate-
reated patients died from multiorgan failure second-
ry to sepsis (days 25 and 192), 1 from interstitial and
MV pneumonia (day 35), 1 from graft failure and
epsis (day 393), 1 from suicide (day 1123), 1 from
uman immunodeﬁciency virus–related causes (day
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Letter to the Editor
5380), 1 from sudden cardiac death (day 5123), and 1
rom cancer of the jaw (day 6111).
We concluded that patients with aplastic anemia
iven HLA-identical marrow grafts and treated with
ethotrexate/cyclosporine had both a signiﬁcantly
ecreased incidence and severity of acute GVHD; this
esulted in a decrease in early transplant-related mor-
ality compared with patients given methotrexate
lone. The early survival advantage has persisted. The
ethotrexate/cyclosporine combination did not re-
igure 1. A, Kaplan-Meier product estimates for overall survival. B,
revalence [3] of chronic GVHD among patients with aplastic
nemia who were administered marrow grafts from HLA-identical
iblings with either methotrexate/cyclosporine (MTX  CSP) or
ethotrexate alone (MTX) for GVHD prophylaxis.uce the incidence of chronic GVHD. With observa- S
68ion times ranging from 18 to 23 years, all methotrexate/
yclosporine-teated patients who developed chronic
VHD have shown resolution of their disease, and im-
unosuppressive therapy has been discontinued.
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